Krebs Biochemicals and Industries balance sheet

As of Sep 2026

Total assets: ₹159cr−5.5% on Sep 2025
Shareholders' equity: −₹171cr−₹158 cr in Sep 2025
Total debt: ₹227cr+3.4% on Sep 2025
Cash and investments: ₹0.1cr−0.9% on Sep 2025

₹ crore except per share

Tap a line for its trend	H1 FY27Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	139	141	145	149	146
	1.6	1.6	1.2	0.2	2.2
	0.2	0.3	0.5	0.7	0.8
	0.0	0.0	1.8	1.8	1.8
	1.6	2.7	2.9	2.5	0.0
	8.3	7.6	7.1	6.2	2.4
	10.0	10.3	10.0	8.8	2.4
	—	—	0.0	0.0	5.1
	151	154	159	161	159
	4.2	5.7	6.0	9.8	11.9
	0.0	0.0	0.1	1.9	0.5
	0.1	0.1	0.1	0.1	0.1
	0.1	0.2	0.2	3.0	0.0
	3.4	3.6	3.8	2.6	0.3
	3.6	3.9	4.2	7.6	0.9
	—	—	0.0	0.0	3.2
	7.8	9.6	10.3	17.4	16.1
	159	163	169	178	175
Equity
	21.6	21.6	21.6	21.6	21.6
	−192	−184	−168	−141	−121
	−171	−163	−146	−119	−99.5
	−171	−163	−146	−119	−99.5
Liabilities
	155	164	161	184	173
	1.1	1.6	2.4	4.0	4.5
	156	165	164	188	178
	2.8	2.8	3.1	3.1	0.3
	45.0	45.0	45.0	45.0	47.3
	203	213	212	236	225
	72.5	61.3	51.0	9.9	10.0
	12.4	13.8	18.2	19.0	15.3
	26.1	22.4	18.2	14.0	10.3
	111	97.4	87.3	42.9	35.5
	0.8	0.7	0.8	1.1	0.7
	14.2	14.9	15.5	17.9	12.8
	126	113	104	61.8	49.1
	329	326	315	297	274
	159	163	169	178	175
Trade payables — MSME split
	0.9	1.2	1.3	—	—
	11.5	12.6	16.9	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

KREBSBIO₹59.15

Krebs Biochemicals and Industries Limited

· Pharma & Health

₹ CrorePeersALPA BALPHARMA VINEETLAB NATCAPSUQ BIOFILCHEM NECLIFE MANGALAM AAREYDRUGSMcap ₹128 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Non-current Assets
+ Property, Plant & Equipment	146.5	149.3	145.2	141.4	139.2
+ Capital Work-in-Progress	2.2	0.2	1.2	1.6	1.6
+ Other Intangibles	0.8	0.7	0.5	0.3	0.2
+ Intangibles under Development	1.8	1.8	1.8	0.0	0.0
+ Long-term Loans	0.0	2.5	2.9	2.7	1.6
+ Other Non-current Financial Assets	2.4	6.2	7.1	7.6	8.3
Non-current Financial Assets	2.4	8.8	10.0	10.3	10.0
+ Other Non-current Assets	5.1	0.0	0.0	—	—
Total Non-current Assets	158.9	160.7	158.8	153.6	151.0
Current Assets
+ Inventories	11.9	9.8	6.0	5.7	4.2
+ Trade Receivables	0.5	1.9	0.1	0.0	0.0
+ Cash & Cash Equivalents	0.1	0.1	0.1	0.1	0.1
+ Short-term Loans	0.0	3.0	0.2	0.2	0.1
+ Other Current Financial Assets	0.3	2.6	3.8	3.6	3.4
Current Financial Assets	0.9	7.6	4.2	3.9	3.6
+ Other Current Assets	3.2	0.0	0.0	—	—
Total Current Assets	16.1	17.4	10.3	9.6	7.8
Total Assets	175.0	178.2	169.0	163.2	158.8
Equity
+ Equity Share Capital	21.6	21.6	21.6	21.6	21.6
+ Other Equity / Reserves	-121.0	-140.8	-167.8	-184.3	-192.2
Equity — Owners of Parent	-99.5	-119.2	-146.2	-162.8	-170.6
Total Equity	-99.5	-119.2	-146.2	-162.8	-170.6
Liabilities
+ Borrowings — Non-current	173.2	183.5	161.3	163.6	154.5
+ Other Non-current Financial Liab	4.5	4.0	2.4	1.6	1.1
Non-current Financial Liabilities	177.7	187.5	163.7	165.2	155.6
+ Provisions — Non-current	0.3	3.1	3.1	2.8	2.8
+ Other Non-current Liabilities	47.3	45.0	45.0	45.0	45.0
Non-current Liabilities	225.3	235.6	211.7	212.9	203.4
+ Borrowings — Current	10.0	9.9	51.0	61.3	72.5
+ Trade Payables	15.3	19.0	18.2	13.8	12.4
+ Other Current Financial Liab	10.3	14.0	18.2	22.4	26.1
Current Financial Liabilities	35.5	42.9	87.3	97.4	111.0
+ Provisions — Current	0.7	1.1	0.8	0.7	0.8
+ Other Current Liabilities	12.8	17.9	15.5	14.9	14.2
Current Liabilities	49.1	61.8	103.5	113.1	126.0
Total Liabilities	274.4	297.4	315.3	326.0	329.4
Total Equity & Liabilities	175.0	178.2	169.0	163.2	158.8
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	—	1.3	1.2	0.9
+ Dues to Other Creditors — Current	—	—	16.9	12.6	11.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.